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ABSTRACT
The strengths and the limitations of research activities currently
present in Europe are explored in order to outline how to pro-
ceed in the near future. Epidemiological and clinical research
and public policy in Europe are generally considered to be com-
prehensive and successful, and the European Renal Association
– European Dialysis and Transplant Association (ERA-EDTA)
is playing a key role in the field of nephrology research. The
Nephrology and Public Policy Committee (NPPC) aims to im-
prove the current situation and translation into public policy by
planning eight research topics to be supported in the coming
5 years by ERA-EDTA.
Keywords: acute kidney injury, big data, cohorts, guidelines,
registry
INTRODUCTION
The goals of this article are to present the current state of the art
of research in epidemiological and clinical nephrology in adults
and children in Europe. It also aims to specify the strengths and
the limitations currently present in Europe in order to explore
how to proceed in the near future. To this end, the article will
also propose a research plan with a few hot topics to be facili-
tated by the European Renal Association – European Dialysis
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and Transplant Association (ERA-EDTA) in the coming years
through stimulating research collaboration and supporting
grant applications to other funding bodies. Finally, it is hoped
that there may be an improvement in screening, diagnosing,
preventing and treating chronic kidney disease (CKD)
(Figure 1).
This article is divided into several sections and written by the
following authors who are members of the Nephrology and
Public Policy Committee (NPPC), an advisory group recently
created to develop the Clinical Nephrology Governance Branch
of the ERA-EDTA [1]:
(i) Kidney disease cohorts in Europe (Kitty Jager,
Benedicte Stengel and Ziad Massy);
(ii) National kidney registries and the ERA-EDTA Registry
(Patrik Finne);
(iii) European paediatric nephrology (Jerome Harambat);
(iv) European Renal Best Practice (ERBP) (Evi Nagler);
(v) Important topics related to the European Union (EU)
priorities (Raymond Vanholder);
(vi) Important clinical research topics in Eastern (Mehmet
Sukru Sever) and Western Europe (Fergus Caskey);
and
(vii) Summary and research proposals (Ziad Massy).
KIDNEY DISEASE COHORTS IN EUROPE
Cohort studies are important tools in medical research when it
comes to investigating risk factors for disease occurrence in the
population and factors related to prognosis in patients. These
studies follow large numbers of individuals and typically collect
data over long periods of time, through prospective cohorts
(which look ahead in time) and retrospective cohorts (which
look back in time). Over the past 15 years, there has been con-
siderable development of cohort studies investigating kidney
diseases worldwide, several of them set up in European coun-
tries. This paragraph takes into consideration the available large
cohorts, though not exhaustively, encouraging future research
collaborations to enhance the scientific potential of the data.
Table 1 lists examples of such studies, investigating CKD, end-
stage kidney disease (ESKD) or, to a lesser extent, acute kidney
injury (AKI) in the general population or in the clinical setting,
initiated or funded by nephrology researchers in one or more
European countries [2–23].
Whereas stand-alone cohort studies are a valuable resource
for research, collaboration on innovative research topics may
further increase both their scientific quality and impact. Some
examples of areas where collaboration may provide added value
include (i) the identification of determinants of outcome where
exposures or events are rare, and numbers in separate cohort
studies may be too small; (ii) the investigation of specific patient
subgroups, such as those defined by age, a specific type of ne-
phropathy or an uncommon patient phenotype; (iii) the con-
current development and external validation of biomarkers or
prediction models; and (iv) the comparison of prevention strat-
egies, clinical practices, services and costs in kidney disease care.
Although several hurdles would need to be overcome re-
garding different data definitions and discrepancies among in-
cluded data, such collaboration may promote further use of
data and biobanks and optimize scientific output. Notably, the
availability of large biobanks in carefully clinically phenotyped
patients is a major strength and provides an opportunity to con-
duct collaborative research designed to uncover non-invasive
diagnostic tests or novel predictive markers of kidney disease
complications and to further improve the classification and
prognostication of kidney diseases, notably based on large-scale
genomic and proteomic data. The identification of the best
form of prevention, clinical and therapeutic practices would
also be enhanced by developing collaborative outcome research
in culturally close populations exposed to different environ-
ments and socioeconomic backgrounds. A few cohorts also
have access to patient-level claim data and hospitalization
records through record linkage with a health administrative
database, thus combining the benefit of well-defined patient
phenotypes with so-called big data. Whether and how such
data can be used for international comparisons would be worth
testing. Such initiatives require funding to help build European
nephrology research networks and infrastructures where data
from various countries can be analysed according to current
European data protection rules. This may provide the opportu-
nity to train nephrologists in clinical epidemiology and include
the support of PhD students and post-doctoral researchers ana-
lysing the collaborative databases. Based on these principles and
with the advantages of existing cohorts, the selection process for
research projects to be supported by the ERA-EDTA may thus
strongly contribute to improve the scientific quality and scope
of clinical research in Europe and evidence-based nephrology
worldwide.
FIGURE 1: Roadmap for ongoing nephrology research for screening,
diagnosing, preventing and treating CKD. Although valuable registry
data and cohort studies exist for defining the current burden of
CKD, novel studies are certainly needed for screening, diagnosing,
preventing and treating this public health problem. Information that
may be gained from future research may be useful for establishing
novel predictive biomarkers for screening and diagnosing CKD, and
thus be useful for creating/implementing guidelines and finally per-
forming interventions for prevention and treatment of CKD.
National societies, kidney foundations, ERA-EDTA and EKHA may
collaborate and support all parties involved in managing the prob-
lems encountered during the planning and the support of these
projects.
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AKI and related metabolic disorders are increasingly recog-
nized to represent significant causes of morbidity and mortality.
Also, AKI is recognized as an important risk factor for CKD as
well as ESKD [24]. With this in mind, the International Society
of Nephrology (ISN) launched the 0by25 AKI initiative to pre-
vent all avoidable deaths from AKI across the world by 2025
[25]. This initiative seems more directed at developing coun-
tries than to European countries. The distinctive features of
AKI in Europe are the ageing population, the association with
multiple organ failure, the advanced technology available for
patient care, the emerging area of onco-nephrology and the fi-
nancial resources that allow care for almost all patients with
AKI [24]. Several cohort studies are presented in Table 1. Since
the committee believes that the study of AKI should be part of
ERA-EDTA’s missions and objectives, additional proposals
should be presented such as the creation of a dedicated nephrol-
ogy network for AKI at the European level to organize, coordi-
nate and improve the practices, research and education in the
field of AKI [24].
NATIONAL KIDNEY REGISTRIES AND THE
ERA-EDTA REGISTRY
Most European countries have their own registries for dialysis
and transplantation patients. Many of these registries are of
high quality with a virtually complete coverage of the patient
population dating back many years. The national and regional
registries have an important role in serving the local nephrology
Table 1. Studies investigating CKD, ESKD or AKI in the general population or in the clinical setting, and initiated or funded by nephrology researchers in
one or more European countries
Cohort studies [Ref.] Country Target population Sample size
General population and primary care cohorts
Berlin Initiative Study [2] DE General population 2069
Esther Study [3] DE General population 9961
Gubbio Study [4] IT General population 5376
Prevention of Renal and Vascular End-stage Disease
Study [5]
NL General population 8592
The Renal Risk in Derby study [6] UK Primary care patients with CKD
Stage 3
1741
Uppsala Longitudinal Study of Adult Men [7] SE Men from the general population 2322
CKD cohorts (adults)
Cardiovascular and Renal Outcome in CKD Stages 2–
4 Patients—The Fourth Homburg evaluation [8]
DE CKD Stages 2–4 444
Chronic Renal Impairment in Birmingham [9] UK CKD Stages 3–5 not on dialysis 382
Multifactorial Approach and Superior Treatment
Efficacy in Renal Patients with the Aid of a Nurse
Practitioner [10]
NL CKD Stages 2–4 788
Grampian Laboratory Outcomes, Morbidity and
Mortality Studies [10]
UK CKD Stages 3–5 not on dialysis 3414
Mild to Moderate Kidney Disease Study [12] DE, AU, IT Patients with primary kidney
disease
227
NephroTest Study [13] FR CKD Stages 3–5 not on dialysis 2084
EQUAL study [14] DE, IT, SE, NL, UK CKD Stages 4–5 and aged >65
years
3500 (target)
The German Chronic Kidney Disease (GCKD) study
[15]
DE CKD Stages 1–5 5217
Chronic Renal Insufficiency Standards
Implementation Study [16]
UK CKD Stages 3–5 not on dialysis 1325
The Chronic Kidney Disease-Renal Epidemiology and
Information Network (CKD-REIN) cohort study [17]
FR CKD Stages 3–5 not on dialysis 3033
MERENA study [18] ES CKD Stages 3–4 1129
The Biobank of Nephrological Diseases in the
Netherlands cohort: the String of Pearls Initiative [19]
NL CKD Stages 1–4 2200
CKD cohorts (children)
4C-Study [20] TR, DE, FR, IT, PL,
UK, AU, RS, PT, CZ,
LT, CH
Children ages 6–17 years old—
GFR of 10–60 mL/min/1.73 m2
688
AKI cohorts
FINNAKI [21] FI ICU patients 2901
PREDICT [22] FR ICU patients 1200
OAKS [23] UK Adults undergoing gastrointesti-
nal resection, liver resection or
reversal of ileostomy or
colostomy
6500
DE, Germany; IT, Italy; NL, the Netherlands; SE, Sweden; AU, Austria; FR, France; ES, Spain; TR, Turkey; PL, Poland; RS, Serbia; PT, Portugal; CZ, Czech Republic; LT, Lithuania;
CH, Switzerland; FI, Finland; FINNAKI study, Finnish Acute Kidney Injury study; OAKS, Outcomes After Kidney injury in Surgery; GFR, glomerular filtration rate; ICU, intensive
care unit.
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communities by publishing annual reports and, for example,
ensuring regional equality of nephrological care within a coun-
try. A central task of these local registries is data collection,
which would be very difficult to organize in a centralized man-
ner in Europe because it requires close collaboration with the
nephrology units, preferably in the local language. On the other
hand, the decentralized data collection has led to heterogeneity
in the data sets between registries.
What data do the national registries provide and what
should they provide to the ERA-EDTA Registry?
Many of the national registries provide the ERA-EDTA
Registry with a core dataset with individual patient data, which
enables international comparisons on essential epidemiological
measures such as incidence and prevalence of kidney replace-
ment therapy (KRT) including kidney transplantation rates and
patient outcomes (ERA-EDTA Annual Report, please consult
www.era-edta-reg.org). Some registries provide aggregate data
rather than individual patient data, which gives basic informa-
tion about KRT in the country.
In recent years, some registries have provided the ERA-
EDTA Registry with an extended data set on clinical perfor-
mance indicators, such as blood pressure and various labora-
tory variables. So far these data have been used in a few research
projects [26, 27], but have not been presented in annual bench-
marking reports. An aim for the future is that more countries
could provide similar data on clinical performance indicators
because this would enable comparison of achievements of treat-
ment targets between countries and initially. This could be
done in a representative sample of patients in order to enhance
feasibility. The collaboration of the ERA-EDTA Registry and
the national registries is clearly a necessary imperative to define
the requested common parameters and explore the feasibility of
such collection.
How can the ERA-EDTA Registry support the national
registries?
The ERA-EDTA Registry is dependent on well-functioning
national and regional registries, which the ERA-EDTA Registry
has supported, mainly by providing know-how. Since 2004, the
Registry staff has organized almost 30 courses on clinical epide-
miology and statistics in various parts of Europe. In addition,
educational articles on epidemiological methods have been
published in Nephrology Dialysis Transplantation, Kidney
International and Nephron Clinical Practice (please consult
www.era-edta-reg.org), and young researchers have been able
to visit the Registry office in Amsterdam to work on research
projects. A central aim must be to continue and develop this
support to national registries as it helps improve the quality and
enhance the conformity of the registries. A large amount of data
is available in the national registries and it is important that this
are analysed and reported by knowledgeable persons.
How to get the most out of the ERA-EDTA Registry
data in order to improve nephrology in Europe?
The data provided to and held by the Registry are needed to
produce information to guide decisions about KRT in Europe.
Many fairly large differences have been observed between coun-
tries and regions, for example, regarding incidence and preva-
lence of KRT and regarding outcomes. This indicates that
treatment policies are different. Efforts should be made to con-
tinue studying international differences and secular trends of
KRT in Europe, and to attempt to find the reasons behind, and
the consequences of, these differences for patient outcomes.
Registry data are commonly used for observational studies,
which have known limitations when comparing effectiveness of
treatments. There is a scarcity of high-quality evidence from
randomized controlled trials (RCT) to guide treatment of dialy-
sis and transplantation patients. The registry-based RCT is an
innovative type of trial that uses registry data to identify the
study subjects and to also collect outcome data [28]. For exam-
ple, randomization protocols could be built into the database
systems of renal registries. When a new patient who fulfils pre-
specified inclusion criteria is reported to the registry, he would
be randomized to an intervention arm and asked for consent.
The intervention must carefully be selected and should be safe
and inexpensive, for example, comparing two compositions of
dialysate. As the inclusion criteria are usually less stringent than
in conventional RCTs, the results may be more generalizable.
As the follow-up data are obtained from registries, the cost is
typically low. One successful example is a Swedish study on
thrombus aspiration during myocardial infarction, which uti-
lized a national registry to recruit and follow-up a large number
of patients at low cost [29]. Registry-based RCTs could be per-
formed in some national renal registries in collaboration with
the ERA-EDTA Registry with especially high-quality data, po-
tentially providing very valuable information that could change
treatment policies in nephrology.
Extension of the present national and regional registry data-
bases to include patients in CKD Stages 4–5 at national levels is
ongoing. It is of crucial importance to stimulate such registries
to collect similar data and use the same definitions so that valid
comparisons can be made in the future. The ERA-EDTA
Registry could serve as a facilitator in this.
EUROPEAN PAEDIATRIC NEPHROLOGY
Past and present situation
In the field of paediatric CKD, the European collaborative
clinical research began 30 years ago with studies conducted by
the ‘European Study Group for Nutritional Treatment of
Chronic Renal Failure in Childhood’ in 25 centres from 8 differ-
ent countries. The research done by this group showed that a
low-protein diet did not affect growth and CKD progression, in
contrast to proteinuria and blood pressure, which were strongly
associated with disease progression [30]. The network then ex-
panded to cover a wider clinical research area, especially in car-
diorenal research. In 2009, the trial entitled ‘Effect of Strict
Blood Pressure Control and ACE Inhibition on the Progression
of CRF in Paediatric Patients’ (ESCAPE) showed that strict
blood pressure control under the 50th percentile slows down
CKD progression during the 5-year follow-up [31]. The initial
antiproteinuric response to the angiotensin-converting enzyme
inhibitor therapy was predictive of a long-term renal survival
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despite the occurrence of proteinuria rebound in half of the
patients [32]. The ESCAPE Network now involves more than
55 centres in 16 European countries and serves as a collabora-
tive platform for major ongoing paediatric projects, such as the
‘Cardiovascular Comorbidity in Children with Chronic kidney
disease’ (4C) study [20, 33], the ‘HDF, Heart and Height’ (3H)
study [34] and the ‘Antibiotic Prophylaxis and Renal Damage
in Congenital Abnormalities of the Kidney and Urinary Tract’
(PREDICT) trial [ClinicalTrials.gov. Antibiotic Prophylaxis
and Renal Damage In Congenital Abnormalities of the Kidney
and Urinary Tract (PREDICT). Accessed at: https://clinical
trials.gov/ct2/show/NCT02021006]. The findings of these proj-
ects concerning the management of how to improve the out-
come of CKD have often been translated into clinical practice
guidelines and implemented in routine clinical settings.
ESKD in children is a specific and extremely challenging
condition that requires large-scale, prospective and cohort stud-
ies. In 2007, a new European registry of paediatric KRT, the
European Society for Paediatric Nephrology (ESPN)/
ERA-EDTA Registry, was launched. Since then, there has been
a progressive increase in the number of European countries
providing individual patient data to the Registry, with 38 coun-
tries—the whole of Europe—currently participating, covering a
general population of more than 100 million children15 years
old. In recent years, the ESPN/ERA-EDTA Registry has suc-
cessfully provided epidemiological data on incidence, preva-
lence, patient characteristics, KRT modalities and mortality in
paediatric ESKD, along with relevant insights on cardiovascular
risk, anaemia, nutrition and growth, dialysis and transplanta-
tion outcomes and rare kidney diseases [35]. The Registry has
yielded several research findings directly relevant to patients,
physicians and healthcare policy makers. For instance, among
more than 6000 children who started dialysis in Europe in the
period between 2000 and 2013, the mortality rate was 28 deaths
per 1000 patients a year [36], more than 50 times higher than in
the general paediatric population without kidney disease. The
mortality rate in Europe is approximately half that reported in
the USA by the United States Renal Data System (USRDS).
Along with other international registries, the ESPN/ERA-
EDTA Registry provided information on the largest cohort of
children starting chronic dialysis in the neonatal period to date
[37]. Given the medical and ethical challenges that arise from
this rare clinical situation, this study provided data of critical
importance showing much improved survival rates. This study
will thus help clinicians to provide reliable prognoses and
counselling to families. Another population-based Registry
study on mortality of children on KRT in 32 European coun-
tries showed considerable variation in the country-specific mor-
tality rate and demonstrated that most of this variance could be
explained through disparities in public health expenditure,
which was inversely associated with mortality risk [38]. In con-
trast to data for adult ESKD, increased healthcare spending pro-
motes patient survival for the vulnerable population of children
on KRT. Other relevant European collaborative efforts in paedi-
atric ESKD include the ‘Cooperative European Paediatric Renal
TransplAnt Initiative’ registry, a multinational paediatric kid-
ney transplantation network [38], and the ‘European Paediatric
Dialysis Working Group’ [39]. In addition, many European
paediatric nephrology centres participate in the global
‘International Paediatric Dialysis Network’ [40].
The main causes of CKD in children are Congenital
Anomalies of Kidney and Urinary Tract and hereditary ne-
phropathies. Continuous advances in cell and molecular biol-
ogy techniques have revolutionized the knowledge, diagnosis
and sometimes even prognosis of many inherited kidney dis-
eases. As the rarity of these diseases creates a barrier for clinical
research, several European networks, registries, disease-specific
databases and bio-repositories have been created to overcome
this issue, with major clinical inputs in genetic counselling, phe-
notypic refinement or genotype–phenotype association, prog-
nostic value and eventually mechanistic insights leading to
therapeutic approaches [41–44]. Furthermore, the European
Rare Kidney Disease Reference Network, a consortium of 38
centres in 12 European countries, has been implemented to
promote dissemination of knowledge, research and healthcare
of rare kidney diseases (ERKNet. The European Rare Kidney
Disease Reference Network. Accessed at: https://www.erknet.
org/index.php? id¼home).
Future epidemiological and clinical research directions
There remain, however, many challenges and areas in which
further epidemiological and clinical research is needed. There is
an increasing emphasis on patient-centred outcome research in
kidney disease but this remains an understudied area of paedi-
atric nephrology (e.g. growth, pubertal development, fatigue,
schooling, absenteeism, familial stress, quality of life and cogni-
tive function). Accurate evaluation of social determinants of
kidney health and integration of social aspects into clinical care
to assist vulnerable families with broad social needs will repre-
sent an important step towards optimization of renal care and
long-term outcomes for children with kidney diseases.
There is unmet need for new drug developments and high-
quality clinical trials in paediatric nephrology research. Recently,
the ‘connect4forchildren’ (C4C) initiative, a new paediatric mul-
tidisciplinary public–private consortium that includes academic
and industry partners from 20 European countries, has been
launched. This network, in which paediatric nephrology is repre-
sented, is a sustainable infrastructure created to facilitate the de-
livery of multinational clinical trials in children.
Finally, further studies are needed to improve patient out-
comes after transitioning from paediatric to adult care. This is a
key issue that should include standardized outcome measures
and time intervals in order to evaluate successful transition pro-
cesses during this high-risk period. This essential research will
require active collaboration between paediatric and adult neph-
rologists and cohorts/registries that allow tracking lifelong
psychosocial and medical outcomes of patients with kidney
disease.
ERBP
Clinical practice guidelines are designed to aid medical
decision-making with the aim of improving care. In theory,
their primary relevance and their quality rely on the rigour of
the underlying development process. During the past decade,
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ERBP has substantially contributed to raising the standards for
guideline developments in nephrology [45]. For every guideline,
an extensive scoping process ensures overlap with other guide-
line bodies is avoided and important questions are addressed
[46]. Decision-making is based on core outcomes that are criti-
cally important to all stakeholders, including patients, their
clinicians and policymakers [46]. Evidence is comprehensively
collected and critically appraised using Cochrane systematic re-
view methodology [47]. Results are subsequently fed into an
evidence-to-statement framework using grading of recommen-
dations assessment, development and evaluation methodology,
which requires guideline developers to carefully consider the
anticipated effects of the options being considered, the certainty
of the evidence for those effects and the costs and feasibility of
options [48]. Patient involvement is encouraged throughout the
development process and every step is executed transparently
with clear documentation of judgements made. Guidelines are
primarily published in Nephrology Dialysis Transplantation,
but co-publication has occurred, depending on the topic [49],
to reach a wider audience. National societies are involved in
translating short versions of the guidelines into various lan-
guages, and dissemination is supported through presentations
during national and international conferences.
In order for guideline development efforts to have signifi-
cance, guideline recommendations must be correctly imple-
mented. Unfortunately, merely developing and disseminating
clinical practice guidelines per se does not ensure their use in
daily renal practice [50]. Several factors related to knowledge,
attitude and behaviour affect their uptake. While ERBP has
invested much effort in producing and disseminating trustwor-
thy guidelines over the years, little is known about their imple-
mentation in practice and any resulting changes in the quality
or outcomes of care.
International and European cohorts and registries with cen-
tre-level data could offer an opportunity for monitoring the
downstream effects of guideline implementation on a national,
European and international scale. Meaningful initiatives would
require informed determination of quality indicators, covering
structure, process and outcome [51, 52]. Such indicators may
overlap with existing quality of care measures, already captured
by existing datasets. One key future goal may require inclusion
of new indicators as part of prospectively collected datasets in
different cohorts and particularly in the ERA-EDTA Registry.
To this end, the QUality European STudies initiative [53]—
taken over by the Registry almost 15 years ago—may be revital-
ized. For any such exercises to be informative, long-term in-
volvement of experts in implementation science will be needed.
Moreover, the promotion for a further and close collaboration
between the two ERA-EDTA entities, the ERBP experts and the
ERA-EDTA Registry staff, should become a key goal in the
future.
IMPORTANT TOPICS RELATED TO THE EU
PRIORITIES
Actions of European kidney health alliance (EKHA) in
the last few years
The constantly rising number of patients with CKD and
ESKD throughout Europe [54] consumes a considerable por-
tion of healthcare budgets [55]. To maintain high-quality care,
a coordinated European approach is needed, which implies or-
ganizational, educational and clinical action, as well as research
planning.
The EKHA (http://ekha.eu/) unites all key European stake-
holders in kidney care (patients, nurses, foundations and physi-
cians), and proposes solutions at the EU policy level for the
challenges posed by CKD, given that both the European
Commission (EC) and European Parliament play vital roles in
assisting national governments via a top-down approach.
EKHA’s work at the EU level is complemented by its contacts
with kidney stakeholder groups at a national level.
With these aims in mind, in 2015, EKHA published its
Recommendations for Sustainable Kidney Care (http://www.re
nal.org/news-item/2015/05/26/ekha-recommendations-for-sus
tainable-kidney-care#sthash.331yWFTZ.dpbs), which are cen-
tred around four main goals: (i) early detection and prevention
of CKD and its progression; (ii) patient education and free
choice of treatment; (iii) increasing access to transplantation;
and (iv) treatment reimbursement strategies.
From 2016 on, EKHA undertook various initiatives to reach
these aims (Table 2) and also organized yearly stakeholder for a
in the European Parliament on these topics, in order to stream-
line activities, draw the attention of European and national
Table 2. EKHA actions
Organization of an Annual European Kidney Forum in the European
Parliament
Participation in the European Commission Conference on chronic
diseases (2014)
Participation at the ASN 2015 Kidney Week stakeholder meeting to
present EKHA as a possible model for collaboration across US
kidney organizations
Participation in the European Commission Conference on food
product improvement (2016)
Contribution to the event ‘Improving organ donation and transplant
across the EU: A cross-condition campaign’ (2016)
Successful advocacy towards EU support of ‘The Effect of Differing
Kidney Disease Treatment Modalities and Organ Donation and
Transplantation Practices on Health Expenditure and Patient
Outcomes’ project (2017–19)
Organization of multi-country survey on patient information (2017)
Contribution to EU Health Policy Platform (2017)
Development of a European Commission Thematic Network on the
Employment of Patients with Chronic Diseases
Collaboration with the EU Joint Action CHRODIS on prevention and
treatment of chronic diseases
Co-drafting of position statements calling for EU action on risk factors
(salt, trans fatty acids, tobacco)
Participation in the drafting of a position statement of the European
ADPKD Federation
Participation in the drafting of the EU Roadmap for Action on Food
Product Improvement
Development of a thematic network on Improving Organ Donation
and Transplantation in the EU for the EU Health policy Platform,
resulting in practical recommendations on how to proceed for the
European Commission (2019)
ADPKD, autosomal dominant polycystic kidney disease; CHRODIS, Chronic Diseases
platform.
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policy makers to these themes and include the involvement of
Members of European Parliament to advance kidney-related
matters.
Prevention is one of the cornerstones of good outcomes and
quality of life, but it is underused. Current CKD cohorts and
population-based cohorts will play a key role in identifying
modifiable risk factors for disease onset and progression, as well
as the best clinical practices. They also have the potential to
point out barriers for successful implementation of primary
and secondary prevention strategies. However, on average in
Member States, only 3% of the health budget is spent on pre-
vention. If part of healthcare financing were shifted from ther-
apy to prevention, this would have a positive impact on total
health expenditure [55]. CKD is linked to many other non-
communicable diseases (NCDs), including diabetes mellitus,
hypertension, cardiovascular disease, cancer and liver disease
[55, 56]. Modifiable measures to reduce incidence of these
NCDs are often related to lifestyle, diet and environment. Since
the same risk factors are common to many chronic diseases,
they require broader action than from the kidney community
alone. In this context, EKHA also has a leading role in the
European Chronic Diseases Alliance, an umbrella consortium
representing 11 chronic disease organizations (http://www.alli
ancechronicdiseases.org/home/).
Not all renal replacement strategies are available to all valid
candidates in all EU countries, and many patients are not well
informed about their options, especially regarding home dialy-
sis (both home haemodialysis and peritoneal dialysis), trans-
plantation and comprehensive conservative (palliative) care
[57]. EKHA confirmed this shortcoming via a recent survey
among patients from several European countries (Table 3).
In addition, the Effect of Differing Kidney Disease
Treatment Modalities and Organ Donation and Transplanta-
tion Practices on Health Expenditure and Patient Outcomes
project, advocated by EKHA at EU level and funded by the
Third Health Programme of the EU, started to assess KRT op-
tion availability and patient information at the beginning of
2017 [58]. Although Europe is one of the leading continents in
transplantation [59], the differences in transplant rate and
number of KRT patients living with a functioning transplant
among countries suggests that there is room for improvement
[59]. Likewise, the differences across Europe between living and
deceased donation show that few countries are strong in both,
and that action should be undertaken to increase by country the
types of donations that occur less [59].
Future actions of the EKHA
Between 2009 and 2015 the EC ran an Action Plan to stimu-
late transplant activities throughout Europe. The plan was par-
tially successful, but more work remains to be done. EKHA
suggests that a second EU Action Plan could further boost
European transplant activity, benefitting from the experience
accumulated during the first programme. EKHA intends to be-
come one of the catalysers for this, drawing from the EKHA
‘gift of life’ campaign launched in 2018 and the EC Thematic
Network on transplantation, which will be developed by EKHA
starting in 2019 (https://www.eurekalert.org/pub_releases/
2018-12/e-epo121718.php).
The reimbursement of KRT is a matter of concern. There
are substantial discrepancies in reimbursement of dialysis
among Member States. The strategies that are least expensive to
the health system (transplantation and home dialysis) are coun-
terintuitively underrepresented throughout Europe. An addi-
tional matter of concern is the appearance of insufficiently
evidenced but costly therapies for rare kidney disorders. All
these factors need further research to guide policy action.
Although the EU has funded several research projects where
kidney disease was the main or an ancillary focus, it is time for a
more coordinated action, in analogy with the ‘Kidney
Innovation Accelerator (KidneyX)’ project run by the US
Department of Health and Human Services, in collaboration
with the American Society of Nephrology (http://www.kidneyx.
org/).
The approach outlined by several Dutch stakeholder groups
(‘Combating Kidney Disease—Nierziekte de baas’) may be
taken as an example for the development of an action plan out-
line (https://www.nierstichting.nl/media/filer_public/14/ef/14e
f1c2a-73f9-40f6-b833-afbc940dbd41/onderzoeksagenda_nierzi
ekte_de_baas_-_gezamenlijke_agenda_oi_2017.pdf). This fra-
mework has four major foci: the much neglected prevention
and quality of life aspects of kidney disease, and the innovatory
fields of personalized and regenerative medicine. This research
framework strives for more sustainable and less costly solutions,
while also considering the scarcity of evidence-based and
health-economic analyses in nephrology [60, 61].
Personalized medicine covers not only tailored treatment for
specific disorders or mechanisms (e.g. the multiple diverging
factors at play in kidney fibrosis and progression of CKD) or
targeted drug administration depending on the individual sen-
sitivity, but also, as health illiteracy is frequent among CKD
patients [62], education (with specific approaches and attention
for the less educated or low income groups as well as ethnic
minorities).
Regenerative medicine programmes focus on bioartificial
organs (the combination of polymers and cells), organoids and
stem cells [63]. Research might also be guided towards often
neglected but troublesome problems for patients, such as itch-
ing, cognitive dysfunction or pain, focusing on patient-centred
outcomes, such as those defined by the Standardised Outcomes
in Nephrology (SONG) initiative (http://songinitiative.org/).
Table 3. Preliminary results of the patient information questionnaire: per-
centage of patients perceiving that they did not receive enough informa-
tion about a given approach
Kidney Replacement or
Conservative Therapies
FR NL SP GR SL LI
Peritoneal dialysis 40 13 36 56 51 41
Home haemodialysis 56 50 48 74 79 65
Overnight haemodialysis 70 50 60 78 71 68
Kidney transplantation 15 17 35 44 30 14
Conservative care 77 64 70 56 90 33
Data are presented as percentage of total responders per country; FR: France; NL: the
Netherlands; SP: Spain; GR: Greece; SL: Slovenia; Li: Lithuania. Data are preliminary
and need more detailed analysis.
NPPC propositions to stimulate research 1475
D
ow
nloaded from
 https://academ
ic.oup.com
/ndt/article-abstract/34/9/1469/5512198 by U
niversite de Bordeaux user on 29 June 2020
Programmes supporting KRT strategies, which favour better
quality of life, are encouraged with focus on projects promoting
and improving transplantation and home therapies. EKHA will
target the hot topics that should be supported in the future by
nephrologists according to the EU needs and will work in col-
laboration with ERA-EDTA to reach these goals.
IMPORTANT CLINICAL RESEARCH TOPICS
IN EUROPE
Western Europe
Beyond registries and cohort studies, there are broadly
speaking three types of health services research—clinical trials,
big data and qualitative (exploratory) research. While there is a
great deal of interesting and important qualitative research go-
ing on to explore ‘why’ things happen using non-numeric data
in Western Europe, qualitative research groups in nephrology
in Western Europe and indeed globally are less well established
than in other research areas. Furthermore, results tend to be
more hypothesis/logic generating and more context-specific
than from other research areas. The committee therefore agreed
that the potential for qualitative research to be world leading,
practice changing and with high impact is less clear at the mo-
ment, and for that reason prefers focusing on existing strengths
and opportunities in clinical trials and big data research.
The conclusions below are based on responses to the follow-
ing questions from four to six experts in each of these two re-
search areas inWestern Europe:
Q1. In what way do you think the region covered by ERA-EDTA is in a
unique position to lead the world in (clinical trials/big data research)
(e.g. existing healthcare infrastructure, information governance and
existing research networks)?
Q2. Can you give 2–3 examples of world-leading (clinical trials/big data
research) conducted in the region covered by the ERA-EDTA in the last
5 years?
Q3. What do you think would be the key 2–3 things that the ERA-EDTA
could do to promote world-leading (clinical trials/big data research) in
Europe?
Clinical trials. A number of major, practice-changing, inves-
tigator-initiated trials have been led by researchers in Western
Europe in recent years. These have been in the areas of vasculi-
tis, membranous glomerulopathy, renal vascular disease and
cholesterol lowering, and demonstrate that it is possible to cre-
ate a network of renal units across Europe to recruit sufficient
numbers to trials. On the contrary, respondents raised concerns
about Western Europe’s ability to recruit to trials and especially
industry-led trials.
Existing collaborations and cultural similarities, along with
the harmonized regulatory process, should facilitate delivery of
large trials across the continent. It was felt that the role of the
ERA-EDTA should be ‘concertation’, that is, bringing academ-
ics and other partners together to define the best questions,
methodology and clinical trial processes. This could be achieved
in a number of ways:
• establishing a network of centres willing to do clinical tri-
als and provide methodological support;
• creating registers of patients willing to be contacted about
clinical trials relevant to them;
• providing educational courses that train investigators to
design and execute trials;
• funding clinical trial fellowships to attach research leaders of
the future to developing projects to help grow the expertise;
• improving the management/presentation/discussion of
trial results at the ERA-EDTA annual conference;
• arranging standalone workshops to examine specific
topics such as end-point design;
• interfacing with regulatory agencies, research funders, in-
dustry and patients to design and deliver trials that are
needed to inform clinical practice;
• fostering closer working with other specialities to reduce
working in a condition-specific silo—some of the future
drugs for kidney diseases are likely to come from develop-
ments in oncology;
• creating a culture of offering patients RCT where evidence
is lacking (similar to oncology); and
• using the ERBP to encourage inclusion in clinical trials,
for example, avoiding expert recommendations when a
clinical trial could be done.
It was felt that the ISN had successfully established a clinical
trials infrastructure Advancing Clinical Trials (ACT), and those
lessons could be learned from that while avoiding duplication.
Big data. Traditionally, Scandinavian countries and those
with nationalized healthcare systems provide an excellent op-
portunity to use routine health and social care records to de-
scribe associations between practices and outcomes in general,
un-selected, populations. There are also, however, some poten-
tially useful general population-level linked datasets in Spain,
France and Switzerland. The new general data protection regu-
lation makes the rules clearer and more consistent and makes it
less difficult to establish a lawful basis for academics to process
personal data for clinical research. There is also heterogeneity
in clinical practice within Western Europe that provides an ex-
cellent opportunity to use observational data to explore the con-
sistency of associations and even the causal nature of
relationships.
It should also be recognized that big data research extends
far beyond linking health and social care records for research; it
can include data from scans, free text and wearable devices, ge-
nomics, proteomics, metabolomics and exposomics.
Both types of big data research can involve the use of prior
hypotheses and statistical models or agnostic approaches such
as machine learning and artificial intelligence. There is certainly
world-leading statistical expertise in Western Europe with con-
siderable potential to apply novel methods of analysis to ne-
phrology if interesting research questions and datasets can be
presented to them. There is less of a track record of machine
learning and artificial intelligence in nephrology in Western
Europe, but the methodological expertise undoubtedly exists.
It was felt that the ERA-EDTA could support the develop-
ment of world-leading big data research in a number of ways:
• establishing a network of researchers with awareness of
and access to routine healthcare databases in different
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countries to facilitate international studies that validate
findings and mine heterogeneity;
• arranging standalone workshops that bring together
nephrologists and methodologists to examine specific
topics;
• facilitating the training of the future big data researchers
through this network and statistical/epidemiological
training courses that take things beyond the introductory
level;
• encouraging the adoption of information standards as
part of renal IT systems to improve data quality for clini-
cal care and research;
• educating the public, policy makers and funders on the
importance of kidney disease and in particular the per-
sonal and societal burden of ESKD, which often gets over-
looked due to its infrequent occurrence;
• dedicating a session at the ERA-EDTA conference to
innovations in big data analysis;
• working out recommendations for which parameters
would be essential to be included in kidney big databases;
and
• stimulating health-economically oriented kidney research
(nephrology traditionally being not being keen to investe
in this area, whereas nephrology is consuming propor-
tionally large chunks of health care budgets).
Eastern Europe
The problems cited below and suggestions for solutions
improvements to these problems are not specific to the Eastern
European countries. However, these problems may be more
prominent in this region of Europe.
• Unique features of nephrological problems in Eastern
Europe. Overall, Eastern Europe includes 10 countries
(Belarus, Bulgaria, Czech Republic, Hungary, Moldova,
Poland, Romania, the Russian Federation, Slovakia and
Ukraine). According to some other sources, additional
countries [Albania, Bosnia-Herzegovina, Croatia, Estonia,
Latvia, Lithuania, Montenegro, Serbia, Former Yugoslav
Republic of Macedonia (FYROM), Georgia, Armenia,
Azerbajan and Turkey] are also classified as being a part
of Eastern Europe. To the best of our knowledge, exten-
sive epidemiologic data on the prevalence of CKD stage
in Eastern Europe in the ERA-EDTA Registry are avail-
able only on CKD Stages 5D and 5T [64]. Only limited
data are available on the prevalence of CKD Stages 3–5
not yet on dialysis, which was considered to be higher
than in Western Europe [65]. Although there are no
comparative trials, it may be speculated, or largely
accepted, that this part of Europe may differ from the
western part in:
• limited funds for both healthcare services and projects;
• less public awareness about chronic diseases, which also
means less attention paid to CKD;
• difficult cooperation with health care authorities;
• country-specific health problems (i.e. Balkan nephropa-
thy, more frequent obesity and diabetes, possibly worse
control of diabetes and hypertension, air pollution and
deviations from recommended diet);
• low transplantation rates in many, but not all, of these
countries [59]; and
• targets/feasibility of these targets.
Since all of the above-mentioned difficulties have potential
negative effects on various aspects (identification, prevention
and treatment) of CKD, actions to be taken may or should tar-
get to improve each of these items. Some of these actions are
more easily achievable (i.e. increasing public awareness,
encouraging-supporting studies on clinical nephrology and epi-
demiology, improving nephrology training), whereas others are
more difficult to achieve (i.e. limited funds and lower standards
for healthcare and problematic cooperation with authorities).
Suggestions by ERA-EDTA and/or EKHA may help contribute
to convincing authorities to make changes, at least in some
countries.
Table 4. Research plan with eight hot topics to stimulate research collaboration and grant applications in Europe
(i) To conduct collaborative research designed to uncover non-invasive diagnostic tests or new predictive markers for kidney disease
complications, aimed to further improve the classification and prognosis of kidney diseases based on large-scale omics data using available
European patient cohorts
(ii) To review the feasibility and relevance of the development of CKD Stages 4–5 registries based on on-going experiences at national level and
explore if and how these can be brought together for quality assurance and research at the European level
(iii) To plan a successful transition process from paediatric to adult care of CKD by active collaboration between paediatric and adult
nephrologists and cohorts/registries
(iv) To reinforce the collaboration between the ERBP experts and ERA-EDTA Registry staff in order to extend the number of indicators to include
the thresholds of the ERBP recommendations as part of prospectively collected datasets stemming from different national or regional
cohorts and from the ERA-EDTA Registry and to adapt those as new recommendations are published
(v) To continue supporting EKHA with its established links with the EU, allowing it to target key nephrological topics prioritized by patients and
professionals, such as better quality of life in KRT patients and improving kidney transplantation and home treatment modalities, which
also include regenerative and personalized medicine
(vi) To support the development of world-leading big data research in a number of ways including the creation of data networks and the
development of educational programmes
(vii) To help the Eastern European nephrology community to optimize patient care and patient-oriented research in their countries by increasing
public awareness, encouraging/supporting clinical nephrology and epidemiology studies and improving training in nephrology
(viii) To create a European network of kidney units in order to extend our understanding of AKI progression and complications, including
transition of AKI to CKD
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Target population. Since CKD is very frequent (mostly af-
fecting 13–15% of the population of the whole country) and a
major cause of morbidity and mortality in addition to having a
huge economic burden, it should be very well understood by:
• healthcare authorities;
• the public; and
• medical professionals, including general practitioners and
specialists with a high probability of seeing CKD patients
(i.e. general internists, cardiologists, diabetologists, endo-
crinologists, urologists, oncologists, hepatologists, vascu-
lar and cardiac surgeons and neurologists).
Thus, the first step should be increasing awareness, and con-
vincing these parties of the importance of CKD.
Detection of CKD. The extent of this problem may differ
across countries; therefore, epidemiologic studies for each of
these countries should be encouraged by healthcare authorities,
national nephrology societies and ERA-EDTA. Conducting
studies on the economic burden of CKD (by medical professio-
nals as well as economists) may help convince authorities to
pay more attention to CKD. Therefore, obtaining current offi-
cial statistics from governmental bodies on both medical and
economical aspects of CKD may be useful to identify the extent
of the problem.
Prevention and treatment. Authorities should be con-
vinced of the importance of CKD and informed that treat-
ment of ESKD is extremely expensive, whereas prevention is
relatively inexpensive and simple.
Pilot and inexpensive projects concerning conservative man-
agement of CKD [such as decreasing salt intake, adopting a
healthy lifestyle, adequate treatment of diabetes and hyperten-
sion, preferably using angiotensin-converting-enzyme (ACE)
inhibitors/Angiotensin receptor blockers (ARBs)] might be ini-
tiated in small areas of the region. Based on early experience
and lessons learned from these pilot initiatives, major country-
wide long-term projects could then be conducted. Close collab-
oration with ERA-EDTAmay be useful for better defining poli-
cies to address these problems.
SUMMARY AND RESEARCH PROPOSALS
Epidemiological and clinical research and public policy is gen-
erally considered to be comprehensive and successful in
Europe, in terms of prosperity and broad coverage. ERA-EDTA
is playing a key role in the field of nephrology research.
However, the NPPC members feel that additional efforts can
help to further improve the current situation and translate into
public policy. The NPPC reached the conclusion that a research
plan with restricted key topics is needed. This project would be
supported by ERA-EDTA in the coming 5 years. Beyond the
support to build RCTs, which is currently operated by ERA-
EDTA, after internal discussion and external consultation of
the ERA-EDTA council, eight projects were selected (Table 4).
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